BrightGene's obesity shot showed strong weight loss data in China, outpacing Lilly's Zepbound in the same market as it nears approval there.
BrightGene looks to the West as obesity shot nears China approval
BrightGene's obesity shot BGM0504 posts strong Phase 3 data in China as it courts a Western partner ahead of a planned global trial.
endpoints.news
July 2, 2026 at 3:01 PM
BrightGene's obesity shot showed strong weight loss data in China, outpacing Lilly's Zepbound in the same market as it nears approval there.
[2/4] its wholly-owned subsidiary Borui Pharmaceutical (Suzhou) Co., Ltd. has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). BGM0504 injection is a dual agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent
June 11, 2026 at 7:49 AM
[2/4] its wholly-owned subsidiary Borui Pharmaceutical (Suzhou) Co., Ltd. has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). BGM0504 injection is a dual agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent
[1/4] 2026-06-11 15:34:44 - [Bori Pharmaceuticals: BGM0504 Injection for Weight Loss Indications New Drug Marketing Application Accepted] Borui Pharmaceuticals announced that the New Drug Application (NDA) for BGM0504 Injection for Weight Loss Indications independently developed by
June 11, 2026 at 7:49 AM
[1/4] 2026-06-11 15:34:44 - [Bori Pharmaceuticals: BGM0504 Injection for Weight Loss Indications New Drug Marketing Application Accepted] Borui Pharmaceuticals announced that the New Drug Application (NDA) for BGM0504 Injection for Weight Loss Indications independently developed by
[2/4] its wholly-owned subsidiary Borui Pharmaceutical (Suzhou) Co., Ltd. has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). BGM0504 injection is a dual agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent
June 11, 2026 at 7:48 AM
[2/4] its wholly-owned subsidiary Borui Pharmaceutical (Suzhou) Co., Ltd. has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). BGM0504 injection is a dual agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent
[1/4] 2026-06-11 15:34:44 - [Bori Pharmaceuticals: BGM0504 Injection for Weight Loss Indications New Drug Marketing Application Accepted] Borui Pharmaceuticals announced that the New Drug Application (NDA) for BGM0504 Injection for Weight Loss Indications independently developed by
June 11, 2026 at 7:48 AM
[1/4] 2026-06-11 15:34:44 - [Bori Pharmaceuticals: BGM0504 Injection for Weight Loss Indications New Drug Marketing Application Accepted] Borui Pharmaceuticals announced that the New Drug Application (NDA) for BGM0504 Injection for Weight Loss Indications independently developed by
[2/4] its wholly-owned subsidiary Borui Pharmaceutical (Suzhou) Co., Ltd. has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). BGM0504 injection is a dual agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent
June 11, 2026 at 7:47 AM
[2/4] its wholly-owned subsidiary Borui Pharmaceutical (Suzhou) Co., Ltd. has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). BGM0504 injection is a dual agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent
[1/4] 2026-06-11 15:34:44 - [Bori Pharmaceuticals: BGM0504 Injection for Weight Loss Indications New Drug Marketing Application Accepted] Borui Pharmaceuticals announced that the New Drug Application (NDA) for BGM0504 Injection for Weight Loss Indications independently developed by
June 11, 2026 at 7:47 AM
[1/4] 2026-06-11 15:34:44 - [Bori Pharmaceuticals: BGM0504 Injection for Weight Loss Indications New Drug Marketing Application Accepted] Borui Pharmaceuticals announced that the New Drug Application (NDA) for BGM0504 Injection for Weight Loss Indications independently developed by
[4/4] diseases. In addition, the indication of BGM0504 injection for type 2 diabetes is currently in phase III clinical trials in China.
May 5, 2026 at 9:20 AM
[4/4] diseases. In addition, the indication of BGM0504 injection for type 2 diabetes is currently in phase III clinical trials in China.
[2/4] weight loss indications independently developed by its wholly-owned subsidiary Borui Pharmaceutical (Suzhou) Co., Ltd. has achieved the expected goals. BGM0504 is a dual agonist of GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors
May 5, 2026 at 9:20 AM
[2/4] weight loss indications independently developed by its wholly-owned subsidiary Borui Pharmaceutical (Suzhou) Co., Ltd. has achieved the expected goals. BGM0504 is a dual agonist of GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors
[1/4] 2026-05-05 17:10:19 - [Bori Pharmaceuticals: The Phase III clinical trial of BGM0504 injection for weight loss indications has achieved the expected goals] Borui Pharmaceuticals (688166) announced on May 5 that recently, the phase III clinical trial of BGM0504 injection for
May 5, 2026 at 9:20 AM
[1/4] 2026-05-05 17:10:19 - [Bori Pharmaceuticals: The Phase III clinical trial of BGM0504 injection for weight loss indications has achieved the expected goals] Borui Pharmaceuticals (688166) announced on May 5 that recently, the phase III clinical trial of BGM0504 injection for
Feed: "Endpoints News"
By: Elizabeth Cairns on Wednesday, June 25, 2025
By: Elizabeth Cairns on Wednesday, June 25, 2025
#ADA25: BrightGene seeks a partner for Zepbound-beating obesity shot
BrightGene's BGM0504 shows 20% weight loss in Phase 2 obesity trial, outperforming Lilly's Zepbound. Company seeks Western partner for global development of the GLP-1/GIP agonist.
endpoints.news
June 26, 2025 at 1:36 PM
Feed: "Endpoints News"
By: Elizabeth Cairns on Wednesday, June 25, 2025
By: Elizabeth Cairns on Wednesday, June 25, 2025
BrightGene Sajikan Data Fase 2 yang Positif untuk Agonis Ganda GLP-1R/GIPR untuk Pengelolaan Berat Badan dan Diabetes Tipe 2 - https://www.antaranews.com/berita/4921053/brightgene-sajikan-data-fase-2-yang-positif-untuk-agonis-ganda-glp-1r-gipr-untuk-pengelolaan-berat-badan-dan-diabetes-tipe-2
BrightGene Sajikan Data Fase 2 yang Positif untuk Agonis Ganda GLP-1R/GIPR untuk Pengelolaan Berat Badan dan Diabetes Tipe 2
BrightGene Pharmaceutical Co., Ltd., perusahaan farmasi internasional yang didorong oleh inovasi, mempresentasikan data dari dua studi Fase 2 untuk BGM0504, ...
www.antaranews.com
June 24, 2025 at 3:27 AM
BrightGene Sajikan Data Fase 2 yang Positif untuk Agonis Ganda GLP-1R/GIPR untuk Pengelolaan Berat Badan dan Diabetes Tipe 2 - https://www.antaranews.com/berita/4921053/brightgene-sajikan-data-fase-2-yang-positif-untuk-agonis-ganda-glp-1r-gipr-untuk-pengelolaan-berat-badan-dan-diabetes-tipe-2
Evolution of GIP as a Core Player in BrightGene Bio-Medical's Latest Weight Loss Breakthrough#China#Suzhou#BGM0504#GIP#BrightGene_Bio-Medical
Evolution of GIP as a Core Player in BrightGene Bio-Medical's Latest Weight Loss Breakthrough
BrightGene Bio-Medical's recent Phase III results spotlight GIP's transformation from a supporting variable to a significant factor in weight loss drugs. Improvements across multiple health metrics are making waves in the pharmaceutical landscape.
third-news.com
May 12, 2026 at 6:12 AM
Evolution of GIP as a Core Player in BrightGene Bio-Medical's Latest Weight Loss Breakthrough#China#Suzhou#BGM0504#GIP#BrightGene_Bio-Medical
BrightGene Bio-Medical's BGM0504 Shows Promising Cardiometabolic Benefits in Phase III Trials#China#Suzhou#cardiometabolic#BrightGene#BGM0504
BrightGene Bio-Medical's BGM0504 Shows Promising Cardiometabolic Benefits in Phase III Trials
BrightGene Bio-Medical's BGM0504 has exhibited significant cardiometabolic improvements and safety in its Phase III clinical trials, marking a shift in weight management strategies.
third-news.com
May 6, 2026 at 5:46 PM
BrightGene Bio-Medical's BGM0504 Shows Promising Cardiometabolic Benefits in Phase III Trials#China#Suzhou#cardiometabolic#BrightGene#BGM0504
BrightGene Unveils Encouraging Phase 1 Results of BGM0504 for Obesity Treatment in China and the U.S.#China#Suzhou#BrightGene#BGM0504#ObesityDrug
BrightGene Unveils Encouraging Phase 1 Results of BGM0504 for Obesity Treatment in China and the U.S.
BrightGene has reported positive topline Phase 1 results for its oral obesity treatment BGM0504, showing safety and preliminary efficacy in both China and the U.S.
third-news.com
March 25, 2026 at 6:43 AM
BrightGene Unveils Encouraging Phase 1 Results of BGM0504 for Obesity Treatment in China and the U.S.#China#Suzhou#BrightGene#BGM0504#ObesityDrug
BrightGene Unveils Promising Results for GLP-1R/GIPR Agonist in Diabetes and Obesity Treatment#China#Suzhou#diabetes#BrightGene#BGM0504
BrightGene Unveils Promising Results for GLP-1R/GIPR Agonist in Diabetes and Obesity Treatment
BrightGene Pharmaceutical has shared groundbreaking Phase 2 data on its dual GLP-1R/GIPR agonist for type 2 diabetes and weight management, along with innovative amylin analog research.
third-news.com
June 24, 2025 at 1:13 AM
BrightGene Unveils Promising Results for GLP-1R/GIPR Agonist in Diabetes and Obesity Treatment#China#Suzhou#diabetes#BrightGene#BGM0504
BrightGene's Phase 2 Study Data Reveals Promising Weight Management Treatments#China#Suzhou#BrightGene#BGM0504#BGM1812
BrightGene's Phase 2 Study Data Reveals Promising Weight Management Treatments
BrightGene reveals positive Phase 2 trial results for its dual GLP-1R/GIPR agonist BGM0504 and a new amylin analogue, showcasing significant potential in diabetes management.
third-news.com
June 24, 2025 at 1:13 AM
BrightGene's Phase 2 Study Data Reveals Promising Weight Management Treatments#China#Suzhou#BrightGene#BGM0504#BGM1812
BrightGene Unveils Promising Phase-2 Data for Weight Regulation and Type-2 Diabetes Treatment#China#Suzhou#BrightGene#BGM0504#BGM1812
BrightGene Unveils Promising Phase-2 Data for Weight Regulation and Type-2 Diabetes Treatment
BrightGene Pharmaceutical unveiled encouraging Phase-2 results at the ADA Conference, highlighting its dual-GLP-1R/GIPR agonist's potential against Type-2 Diabetes and obesity.
third-news.com
June 24, 2025 at 1:12 AM
BrightGene Unveils Promising Phase-2 Data for Weight Regulation and Type-2 Diabetes Treatment#China#Suzhou#BrightGene#BGM0504#BGM1812
BrightGene Unveils Promising Phase 2 Data on Its Dual Agonist for Weight Management and Type 2 Diabetes#China#Suzhou#diabetes_treatment#BrightGene#BGM0504
BrightGene Unveils Promising Phase 2 Data on Its Dual Agonist for Weight Management and Type 2 Diabetes
BrightGene Pharmaceutical Company presents significant Phase 2 findings for its dual GLP-1R/GIPR agonist aimed at tackling weight management and Type 2 diabetes, showcasing potential advancements in treatment options.
third-news.com
June 24, 2025 at 1:12 AM
BrightGene Unveils Promising Phase 2 Data on Its Dual Agonist for Weight Management and Type 2 Diabetes#China#Suzhou#diabetes_treatment#BrightGene#BGM0504
BrightGene Unveils Promising Phase 2 Data for Weight Management and Diabetes Treatments#China#Suzhou#BrightGene#BGM0504#BGM1812
BrightGene Unveils Promising Phase 2 Data for Weight Management and Diabetes Treatments
BrightGene has announced positive Phase 2 results for BGM0504, a new dual GLP-1R/GIPR agonist, and preclinical data for BGM1812, showcasing their potential in weight management and diabetes treatment.
third-news.com
June 24, 2025 at 1:04 AM
BrightGene Unveils Promising Phase 2 Data for Weight Management and Diabetes Treatments#China#Suzhou#BrightGene#BGM0504#BGM1812
